Wilms Tumor

Amanda F Saltzman; Nicholas G Cost; Rodrigo L P Romao

doi:10.1016/j.ucl.2023.04.008

Wilms Tumor

Urol Clin North Am. 2023 Aug;50(3):455-464. doi: 10.1016/j.ucl.2023.04.008. Epub 2023 May 18.

Authors

Amanda F Saltzman¹, Nicholas G Cost², Rodrigo L P Romao³

Affiliations

¹ Department of Urology, University of Kentucky, Lexington, KY, USA.
² Division of Urology, Department of Surgery, University of Colorado School of Medicine, 13123 East 16th Avenue, B 463, Aurora, CO 80045, USA; Surgical Oncology Program, Children's Hospital Colorado, 13123 East 16th Avenue, B 463, Aurora, CO 80045, USA. Electronic address: nicholas.cost@childrenscolorado.org.
³ Department of Surgery, IWK Health Centre, Dalhousie University, Halifax, Canada; Department of Urology, IWK Health Centre, Dalhousie University, Halifax, Canada.

PMID: 37385707
DOI: 10.1016/j.ucl.2023.04.008

Abstract

Wilms tumor (WT), or nephroblastoma, is the most common primary malignant renal tumor of childhood. It is an embryonal tumor that develops from remnants of immature kidney. There are approximately 500 new WT cases diagnosed in the United States every year. Advances in multimodal therapy including surgery, chemotherapy, and radiation therapy given according to risk stratification have allowed most patients to achieve survival rates in excess of 90%.

Keywords: Nephrectomy; Nephroblastoma; Renal tumor; Urologic oncology; Wilms tumor.

Publication types

Review

MeSH terms

Combined Modality Therapy
Humans
Kidney
Kidney Neoplasms* / therapy
Neoplasms, Germ Cell and Embryonal*
Wilms Tumor* / therapy